Optimizing parameters in clinical trials with a randomized start or withdrawal design

[1]  J. Bunch,et al.  Differential Vulnerability , 2016 .

[2]  F. Mantelli,et al.  Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease , 2013, British Journal of Ophthalmology.

[3]  M. Sano,et al.  A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease , 2011, Neurology.

[4]  P. Aisen,et al.  A phase II trial of huperzine A in mild to moderate Alzheimer disease , 2011, Neurology.

[5]  B. Brunekreef,et al.  Methodological Issues and Statistical Analysis in Land Use Regression Modeling , 2011 .

[6]  Mark A Mintun,et al.  Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.

[7]  J. Morris,et al.  Longitudinal study of the transition from healthy aging to Alzheimer disease. , 2009, Archives of neurology.

[8]  C. Xiong,et al.  Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: Opportunities and challenges , 2009, Alzheimer's & Dementia.

[9]  Shein-Chung Chow,et al.  Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.

[10]  J. Cummings,et al.  Disease-modifying therapies in Alzheimer’s disease ⁎ ⁎ EDITOR’S NOTE: The Journal intended to include this article in the January 2008 supplement, “Leon Thal Symposium on Prevention of Dementia.” , 2008, Alzheimer's & Dementia.

[11]  J. Cummings Optimizing phase II of drug development for disease-modifying compounds , 2008, Alzheimer's & Dementia.

[12]  Christopher Clark,et al.  Disease-modifying therapies for Alzheimer disease , 2007, Neurology.

[13]  J. Frédéric Bonnans,et al.  Numerical Optimization: Theoretical and Practical Aspects (Universitext) , 2006 .

[14]  P. Aisen Commentary on “Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials” , 2006, Alzheimer's & Dementia.

[15]  Jeffrey L. Cummings,et al.  Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials , 2006, Alzheimer's & Dementia.

[16]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[17]  J Philip Miller,et al.  Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI , 2006, Neurology.

[18]  C. Sampaio Alzheimer disease: disease modifying trials; where are we? Where do we need to go? A reflective paper. , 2006, The journal of nutrition, health & aging.

[19]  O. Rascol,et al.  Disease modifying trials in Alzheimer disease: methodological and statistical issues. , 2006, The journal of nutrition, health & aging.

[20]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[21]  Yvette I. Sheline,et al.  Potential antecedent marker of Alzheimer disease , 2006 .

[22]  Hendrik van den Bussche,et al.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.

[23]  M. Citron,et al.  Strategies for disease modification in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[24]  D. Head,et al.  Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. , 2004, Cerebral cortex.

[25]  R. Mani The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint , 2004, Statistics in medicine.

[26]  F. Schmitt,et al.  Designing a large prevention trial: statistical issues , 2004, Statistics in medicine.

[27]  V. Gebski,et al.  Inclusion of patients in clinical trial analysis: the intention‐to‐treat principle , 2003, The Medical journal of Australia.

[28]  D. Jarjoura Crossing controls to treatment in repeated-measures trials. , 2003, Controlled clinical trials.

[29]  Jean Charles Gilbert,et al.  Numerical Optimization: Theoretical and Practical Aspects , 2003 .

[30]  G H Guyatt,et al.  Intention-to-treat principle. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[31]  L. Thal,et al.  Clinical trial designs for demonstrating disease-course-altering effects in dementia. , 1998, Alzheimer disease and associated disorders.

[32]  A Whitehead,et al.  Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. , 1998, JAMA.

[33]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[34]  P Leber,et al.  Slowing the progression of Alzheimer disease: methodologic issues. , 1997, Alzheimer disease and associated disorders.

[35]  R. Berger,et al.  Uniformly More Powerful, One-sided Tests for Hypotheses about linear Inequalities , 1995 .

[36]  P. Diggle Analysis of Longitudinal Data , 1995 .

[37]  E. M. Chi Analysis of Cross‐Over Trials When Within‐Subject Errors Follow an AR(1) Process , 1992 .

[38]  Roger L. Berger,et al.  Uniformly More Powerful Tests for Hypotheses concerning Linear Inequalities and Normal Means , 1989 .

[39]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[40]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[41]  Roger L. Berger,et al.  Testing Hypotheses concerning Unions of Linear Subspaces , 1984 .

[42]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[43]  B. Noble Applied Linear Algebra , 1969 .